Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma
暂无分享,去创建一个
M. Sokołowska-Wojdyło | R. Nowicki | E. Bien | M. Sobjanek | M. Sikorska | M. Lange | M. Zabłotna | E. Bień
[1] O. Boyman,et al. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. , 2014, Current opinion in chemical biology.
[2] Y. Fukabori,et al. Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma , 2014, BioMed research international.
[3] B. Lippitz,et al. Cytokine patterns in patients with cancer: a systematic review. , 2013, The Lancet. Oncology.
[4] Sheri L. Johnson,et al. Tumor Site Immune Markers Associated with Risk for Subsequent Basal Cell Carcinomas , 2011, PLoS ONE.
[5] Yesheng Wei,et al. Association of the interleukin-2 polymorphisms with interleukin-2 serum levels and risk of nasopharyngeal carcinoma. , 2010, DNA and cell biology.
[6] Bai-Cheng He,et al. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. , 2009, International journal of oncology.
[7] Hsu-Chueh Ho,et al. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma , 2009, Acta oto-laryngologica.
[8] L. Medenica,et al. Cytokine concentrations in basal cell carcinomas of different histological types and localization. , 2008, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.
[9] T. Nomura,et al. Regulatory T Cells and Immune Tolerance , 2008, Cell.
[10] E. Tartour,et al. Soluble interleukin‐2 receptor and metalloproteinase‐9 expression in head and neck cancer: prognostic value and analysis of their relationships , 2007, Clinical and experimental immunology.
[11] T. Waldmann. Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey , 2007, Journal of Clinical Immunology.
[12] A. Balcerska,et al. Serum level of soluble interleukin-2 receptor α correlates with the clinical course and activity of Wilms’ tumour and soft tissue sarcomas in children , 2007, Biomarkers.
[13] T. Waldmann,et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. , 2006, Blood.
[14] Prahbjot Kaur,et al. Basal Cell Carcinoma Progression Correlates With Host Immune Response and Stromal Alterations: A Histologic Analysis , 2006, The American Journal of dermatopathology.
[15] T. Gambichler,et al. Cytokine mRNA expression in basal cell carcinoma , 2006, Archives of Dermatological Research.
[16] G. Botti,et al. Soluble interleukin-2 receptor in stage I-III melanoma. , 2006, Cytokine.
[17] R. Dummer,et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. , 2003, Archives of dermatology.
[18] S. Murakami,et al. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer , 2002, International Journal of Clinical Oncology.
[19] T. Waldmann. The IL-2/IL-15 Receptor Systems: Targets for Immunotherapy , 2002, Journal of Clinical Immunology.
[20] E. Tartour,et al. Serum soluble interleukin–2 receptor concentrations as an independent prognostic marker in head and neck cancer , 2001, The Lancet.
[21] R. Moy,et al. Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. , 2000, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[22] G. Halliday,et al. Cytokine profiles in spontaneously regressing basal cell carcinomas , 2000, The British journal of dermatology.
[23] T. Waldmann,et al. IL-2R alpha on one cell can present IL-2 to IL-2R beta/gamma(c) on another cell to augment IL-2 signaling. , 1998, Journal of immunology.
[24] M. Wasik,et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. , 1998, Journal of the American Academy of Dermatology.
[25] G. Halliday,et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells , 1995, World Journal of Surgery.
[26] D. Nelson,et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.
[27] A. Balcerska,et al. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[28] T. Yoshikawa,et al. Inhibition of peritoneal metastasis in an animal gastric cancer model by interferon-gamma and interleukin-2. , 2003, Anticancer Research.
[29] K. Chow,et al. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] S. von Kleist,et al. Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma , 1993, Cancer.